A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Overview and Recent Developments We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications. Our pipeline includes: •LTI-03, a peptide for which we conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, or IPF, that has demonstrated the ability in both preclinical studies and clinical trials to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; •LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -59M | -63M | -16M | -27M | -26M | -27M |
| EPS | $-2.94 | $-3.51 | $-3.42 | $-6.02 | $-5.89 | $-0.61 |
| Free Cash Flow | 0 | -22M | -20M | -25M | -24M | -20M |
| ROIC | -130.1% | -94.6% | -16.0% | -117.3% | -59.6% | -133.1% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.14 | 0.08 | 0.18 | 0.10 | 0.34 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -61M | -65M | -16M | -28M | -27M | -20M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -130.8% | -82.4% | -26.9% | -87.4% | -93.3% | -193.8% |
| Shares Outstanding | 26M | 18M | 5M | 5M | 4M | 45M |
Rein Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Rein Therapeutics, Inc. (RNTX) has a 5-year average return on invested capital (ROIC) of -84.1%. This is below average and may indicate limited pricing power.
Rein Therapeutics, Inc. (RNTX) has a market capitalization of $43M. It is classified as a small-cap stock.
Rein Therapeutics, Inc. (RNTX) does not currently pay a regular dividend.
Rein Therapeutics, Inc. (RNTX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Rein Therapeutics, Inc. (RNTX) generated $-22 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Rein Therapeutics, Inc. (RNTX) has a debt-to-equity ratio of 0.14. This indicates a conservatively financed balance sheet.
Rein Therapeutics, Inc. (RNTX) reported earnings per share (EPS) of $-3.51 in its most recent fiscal year.
Rein Therapeutics, Inc. (RNTX) has a return on equity (ROE) of -82.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 10 years of financial data for Rein Therapeutics, Inc. (RNTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Rein Therapeutics, Inc. (RNTX) has a book value per share of $3.04, based on its most recent annual SEC filing.